Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Treace Medical Concepts (TMCI) Shares Outstanding (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Shares Outstanding readings, the most recent being $63.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 2.41% to $63.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.9 million, a 2.41% increase, with the full-year FY2025 number at $63.9 million, up 2.41% from a year prior.
  • Shares Outstanding hit $64.0 million in Q4 2025 for Treace Medical Concepts, up from $63.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $64.0 million in Q4 2025 to a low of $38.1 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $61.6 million (2023), compared with a mean of $58.4 million.
  • Biggest five-year swings in Shares Outstanding: changed 0.0% in 2021 and later surged 726.6% in 2022.
  • Treace Medical Concepts' Shares Outstanding stood at $54.2 million in 2021, then rose by 2.67% to $55.6 million in 2022, then rose by 11.0% to $61.7 million in 2023, then rose by 0.99% to $62.4 million in 2024, then increased by 2.41% to $63.9 million in 2025.
  • The last three reported values for Shares Outstanding were $63.9 million (Q4 2025), $63.7 million (Q3 2025), and $63.0 million (Q2 2025) per Business Quant data.